Abstract
Herpes Simplex Virus (HSV) has a number of advantages as a gene delivery vector, particularly for the nervous system. Thus, it naturally establishes asymptomatic latent infections of neuronal cells. Moreover, it is readily grown in culture to high titre and has a large genome so allowing it to be used to deliver multiple or very large genes. Considerable progress has been made in effectively disabling the virus so that it does not damage the cells it infects but can still deliver an inserted gene effectively. In addition, it is now possible to obtain long-term expression of the transgene in the nervous system, using regulatory elements derived from the latency-associated transcript of the virus. As well as its use in the nervous system, the virus has also been used to successfully deliver genes to a variety of other cell types, including peripheral blood mononuclear cells and cardiac myocytes within the intact heart. In particular, its ability to deliver genes effectively to replicating cancer cells and to dendritic cells offers considerable potential for the use of this virus in cancer therapy.
Current Gene Therapy
Title: Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types
Volume: 2 Issue: 4
Author(s): David S. Latchman
Affiliation:
Abstract: Herpes Simplex Virus (HSV) has a number of advantages as a gene delivery vector, particularly for the nervous system. Thus, it naturally establishes asymptomatic latent infections of neuronal cells. Moreover, it is readily grown in culture to high titre and has a large genome so allowing it to be used to deliver multiple or very large genes. Considerable progress has been made in effectively disabling the virus so that it does not damage the cells it infects but can still deliver an inserted gene effectively. In addition, it is now possible to obtain long-term expression of the transgene in the nervous system, using regulatory elements derived from the latency-associated transcript of the virus. As well as its use in the nervous system, the virus has also been used to successfully deliver genes to a variety of other cell types, including peripheral blood mononuclear cells and cardiac myocytes within the intact heart. In particular, its ability to deliver genes effectively to replicating cancer cells and to dendritic cells offers considerable potential for the use of this virus in cancer therapy.
Export Options
About this article
Cite this article as:
Latchman S. David, Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types, Current Gene Therapy 2002; 2 (4) . https://dx.doi.org/10.2174/1566523023347698
DOI https://dx.doi.org/10.2174/1566523023347698 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
miR-221/222 Confers Radioresistance in Glioblastoma Cells Through Activating Akt Independent of PTEN Status
Current Molecular Medicine Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Comparing the Interaction of Cyclophosphamide Monohydrate to Human Serum Albumin as Opposed to Holo-Transferrin by Spectroscopic and Molecular Modeling Methods: Evidence for Allocating the Binding Site
Protein & Peptide Letters Therapeutic Targeting of Melanoma Cells Using Neural Stem Cells Expressing Carboxylesterase, a CPT-11 Activating Enzyme
Current Stem Cell Research & Therapy In Vitro Intestinal Co-Culture Cell Model to Evaluate Intestinal Absorption of Edelfosine Lipid Nanoparticles
Current Topics in Medicinal Chemistry Editorial
Current Radiopharmaceuticals DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide
Reviews on Recent Clinical Trials The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents MMPs in Ovarian Cancer as Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Naturally-occurring Dimers of Flavonoids as Anticarcinogens
Anti-Cancer Agents in Medicinal Chemistry mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design PLGA Hollow Microbubbles Loaded with Iron Oxide Nanoparticles and Doxorubicin for Dual-mode US/MR Imaging and Drug Delivery
Current Nanoscience PET Tracers for Mapping Adenosine Receptors as Probes for Diagnosis of CNS Disorders
Central Nervous System Agents in Medicinal Chemistry Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Synthesis of [<sup>64</sup>Cu]Cu-NOTA-Bn-GE11 for PET Imaging of EGFR-Rich Tumors
Current Radiopharmaceuticals